Can someone describe how Cubist's tedizolid compares to Durata's dalvacin? They are both set for review on same day.
Can anyone describe how Cubist's tedizolid compares to Durata's dalvacin? They are both set for review on same day and for the same indication.Cubist website doesn't give much info on tedizolid. Is tedizolid also an IV antibiotic? Is there some basis that Durata's dalvacin will gain more market share than Cubist's tedizolid? What are the differences and what has the data shown for both drugs that could give dalvacin a marketing edge? I am long Durata.
It's really easy- tedlizolid is a second generation oxazolidinone antibiotic, so it's much like Zyvox (also comes in oral and iv form). It is given once daily. As it can only be said that tedizolid is noninferior to Zyvox, it can be inferred that it would be used in the same way- either as a switch from Vanco when the patient gets discharged from the Hospital or as first line therapy for those rare folks that can't take vanco. It cannot be considered a competitor to DRTX.
What makes dalvacin special (as I'm sure you know) is that it's only given once weekly x2 and inpatient admission is not necessary. The only thing similar on the horizon if oritavancin and the FDA isn't ruling on that until August.
One thing to watch out for in comparing relative worth of tedizolide and dalvancin is the promise the former has in treating MRSA sepsis and pneumonia. It's pharmacology suggests it will be superior to daptomycin, Zyvox, or IV Vanco. The sub acute skin infection indication is the foot in the door for both but only Ted has the likelihood of being the best drug in a crisis.
That said, I'm an ER doc who can easily see using lots of dalvancin.